Fueled by enterprise customer growth, QbDVision secures $13MM in strategic investment to accelerate Digital CMC transformation

After a year of breakthrough successes, QbDVision has secured $13M in additional investment fueled by rapid enterprise customer growth that now includes three of the top six pharma and biotech companies, successful global deployments, and the increased demand for its category-defining Digital CMC platform, which addresses the increasing need for digitalization of development and manufacturing work streams across the entire product lifecycle for pharma and biotech.

Led by prior investors Northpond Ventures and S3 Ventures, along with Create Health Ventures and company insiders, this new capital infusion accelerates the realization of our shared vision and the opportunity at hand: solidifying QbDVision as the digital knowledge backbone for Chemistry, Manufacturing, and Controls (CMC) workflows that will enable tomorrow’s AI-powered pharmaceutical industry.